Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis - Related Studies

Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis

This study is ongoing, but not recruiting participants.

Study NCT00418847. Last updated on January 4, 2007. Information provided by The Hospital for Sick Children

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Gangliosidoses GM2

2	Additional conditions recognized in this trial
		Gangliosidoses
		Gangliosidoses, GM2
		Tay-Sachs Disease

3	More general conditions related to this trial
		Brain Diseases
		Brain Diseases, Metabolic
		Brain Diseases, Metabolic, Inborn
		Central Nervous System Diseases
		Genetic Diseases, Inborn
		Lipid Metabolism Disorders
		Lipid Metabolism, Inborn Errors
		Lipidoses
		Lysosomal Storage Diseases
		Lysosomal Storage Diseases, Nervous System
		Metabolic Diseases
		Metabolism, Inborn Errors
		Nervous System Diseases
		Sphingolipidoses

4	Interventions listed in this trial
		miglustat

5	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antiviral Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		The Hospital for Sick Children
		Actelion